4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000950170-24-032989
Chief Executive Officer sold 20,000 shares at an average $72.48 ($1,449,628)
- Chief Executive Officer acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2024-03-15 | Option exercise 10b5-1 | +20,000 | $19.12 | $382,400 | 228,122 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-03-15 | Sale 10b5-1 | −10,613 | $71.97 | $763,810 | 217,509 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-03-15 | Sale 10b5-1 | −9,387 | $73.06 | $685,818 | 208,122 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2024-03-15 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 19,582 | D | ||
| Open-market sales · 20,000 sh · avg $72.48 · $1,449,628 | |||||||
Loading xslF345X05/ownership.xml…